Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

ALNY

Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALNY
DateTimeSourceHeadlineSymbolCompany
21/05/202406:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
21/05/202406:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
21/05/202406:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
21/05/202406:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
21/05/202406:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
21/05/202406:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
21/05/202406:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
21/05/202406:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
21/05/202406:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
21/05/202406:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
21/05/202406:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/05/202422:00Business WireAlnylam Issues 2023 Corporate Responsibility ReportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
02/05/202422:00Business WireAlnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period ActivityNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/04/202421:00PR Newswire (US)Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including AustraliaNASDAQ:ALNYAlnylam Pharmaceuticals Inc
30/04/202421:00PR Newswire (Canada)Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including AustraliaNASDAQ:ALNYAlnylam Pharmaceuticals Inc
18/04/202422:00Business WireAlnylam to Webcast Conference Call Discussing First Quarter 2024 Financial ResultsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
07/04/202422:00Business WireAlnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled HypertensionNASDAQ:ALNYAlnylam Pharmaceuticals Inc
20/03/202423:00Business WireAlnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific SessionNASDAQ:ALNYAlnylam Pharmaceuticals Inc
13/03/202422:30Business WireAlnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive DiseaseNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202422:50Business WireAlnylam meldet positive KARDIA-2 Topline-Studienergebnisse, die eine klinisch signifikante Blutdrucksenkung bei Zugabe von Zilebesiran zu Standard-Blutdrucksenkern belegenNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202409:39Business WireAlnylam annonce des résultats positifs de l’étude KARDIA-2 démontrant des réductions cliniquement significatives de la pression artérielle lorsque le zilebesiran est ajouté à des antihypertenseurs standardsNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202408:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202408:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202408:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
06/03/202408:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202423:30Business WireAlnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care AntihypertensivesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
05/03/202408:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALNYAlnylam Pharmaceuticals Inc
01/03/202408:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
01/03/202408:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
01/03/202408:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALNYAlnylam Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:ALNY